Tandem Diabetes Care, Inc. Q4 2025 Earnings Call Summary

Surpassed $1 billion in annual sales in 2025, driven by record fourth-quarter pump shipments and double-digit growth in both U.S. and international markets.

Management is fundamentally reshaping the business model by transitioning to a ‘pay-as-you-go’ (PayGo) reimbursement structure in the pharmacy channel to reduce patient out-of-pocket barriers.

The shift to pharmacy is expected to double the lifetime revenue per patient while streamlining the prescription process for healthcare providers and improving data visibility for payers.

International growth was supported by record sales despite the operational complexity of transitioning to direct commercial operations in the U.K., Switzerland, and Austria.

Operational efficiency improved significantly, with Q4 gross margins reaching a record 58% due to manufacturing efficiencies and a reduction in non-cash stock-based compensation.

The company expanded its addressable market in 2025 by launching Control-IQ+ for type 2 diabetes and integrating with FreeStyle Libre 3 Plus for t:slim, with plans to launch Dexcom’s 15-day sensor integration in the second quarter of 2026.

2026 guidance assumes 10% to 11% growth in U.S. pump shipments, though revenue growth will be moderated by a $70 million to $80 million pricing headwind from the PayGo transition.

Management expects the pharmacy channel to eventually represent over 70% of U.S. shipments within 2 to 3 years, flipping the current 80% reliance on the DME channel.

The company plans to file for FDA 510(k) clearance for Mobi Tubeless in Q2 2026, targeting a launch in the second half of the year as the world’s first patch pump with extended wear technology.

International direct operations will expand to additional European markets in Q4 2026, with anticipated ASP premiums of at least 30% over current distributor pricing.

Financial targets for 2026 include expanding gross margins to 56%-57% and achieving positive adjusted EBITDA of 5%-6% for the full year.

The transition to direct international operations includes a $15 million headwind in 2026 related to distributor destocking and inventory buybacks.

The PayGo model creates a near-term revenue ‘offset’ because pump revenue is recognized over time via supply sales rather than as a large upfront payment.

Q1 2026 results are expected to reflect typical seasonality, including a nearly 30% decline in shipments from Q4 due to U.S. insurance deductible resets.

Management identified the need for new physician prescriptions as a minor friction point in transitioning the existing 325,000-customer base to the pharmacy channel.